Skip to main content

Table 1 Clinical characteristics of 5–2-1-positive and 5–2-1-negative patients

From: Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

 

All patients (n = 4714)a

5–2-1 positive (n = 1546)a

5–2-1 negative (n = 3168)a

P-value

Patient age

 Mean (SD)

69.3 (10.6)

71.7 (10.4)

68.2 (10.5)

< 0.0001

 ≥65 years, n (%)

3309 (70.2)

1231 (79.6)

2078 (65.6)

< 0.0001

Gender, n (%)

 Male

2866 (60.8)

964 (62.4)

1902 (60.0)

0.1274

Charlson Comorbidity Index, mean (SD)

0.4 (1.0)

0.6 (1.2)

0.3 (0.9)

< 0.0001

Charlson Comorbidity Index, n (%)

 None (score 0)

3765 (79.9)

1108 (71.7)

2657 (83.9)

< 0.0001

 Mild (score 1–2)

787 (16.7)

357 (23.1)

430 (13.6)

 

 Moderate (score 3–4)

120 (2.5)

62 (4.0)

58 (1.8)

 

 Severe (score 5+)

42 (0.9)

19 (1.2)

23 (0.7)

 

Time since PD diagnosis (years), mean (SD)

4.3 (4.4) (n = 3712)

7.2 (5.1) (n = 1162)

3.0 (3.2) (n = 2550)

< 0.0001

Physician judgment of PD stage, n (%)

 Non-advanced

4012 (85.1)

994 (64.3)

3018 (95.3)

< 0.0001

 Advanced

702 (14.9)

552 (35.7)

150 (4.7)

 

Hoehn and Yahr stage, n (%)

 1

1593 (33.8)

1579 (39.4)

14 (2.0)

< 0.0001

 2

1545 (32.8)

1492 (37.2)

53 (7.5)

 

 3

932 (19.8)

778 (19.4)

154 (21.9)

 

 4

457 (9.7)

147 (3.7)

310 (44.2)

 

 5

187 (4.0)

16 (0.4)

171 (24.4)

 
  1. PD Parkinson’s disease, SD Standard deviation
  2. aPatient number unless otherwise stated